New York, NY -- (SBWIRE) -- 12/27/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Frontline Ltd (NYSE:FRO), Atlantic Power Corp (NYSE:AT), Vical Incorporated (NASDAQ:VICL), CytRx Corporation (NASDAQ:CYTR)
Frontline Ltd (NYSE:FRO) showed a volume of 1.84 million shares by the end of last trade whereas the average volume of the stock remained 1.55 million shares. The stock opened the session at $3.87 but then moved to $3.85. At that price, the stock showed a positive performance of 1.85%. Frontline Ltd. is a Bermuda-based shipping company engaged primarily in the ownership and operation of oil tanker. The Company operates oil tankers of two sizes: Very Large Crude Carriers (VLCCs), which are between 200,000 and 320,000 deadweight tonnages (dwt), and Suezmax tankers, which are vessels between 120,000 and 170,000 dwt. The Company operates through subsidiaries and partnerships located in the Bahamas, Bermuda, the Cayman Islands, India, the Isle of Man,
Will FRO Continue To Move Higher? Find Out Here
Atlantic Power Corp (NYSE:AT) opened the session at $3.27 and closed the session at $3.45. The stock showed a positive performance of 5.50% in previous trading session. Traded with volume of 1.81 million shares in the prior session and the average volume of the stock remained 1.44 million shares. Atlantic Power Corporation (Atlantic Power) owns and operates a fleet of power generation and infrastructure assets in the United States and Canada. The Company’s power generation projects sell electricity to utilities and industrial customers under long-term power purchase agreements. During the year ended December 31, 2011, its power generation projects in operation had an aggregate gross electric generation capacity of approximately 3,397 megawatts in which its ownership interest was approximately 2,140 megawatts. The Company operates in five segments: Northeast,
For How Long AT will fight for Profitability? Read This Trend Analysis report
Vical Incorporated (NASDAQ:VICL) opened the session at $1.22 and closed the session at $1.19. The stock showed a negative performance of -1.65% in previous trading session. Traded with volume of 1.77 million shares in the prior session and the average volume of the stock remained 1.11 million shares. The beta of the stock remained 1.50. Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent clinical and preclinical development programs in the areas of infectious disease and cancer, including a fully enrolled Phase III clinical trial using its Allovectin immunotherapeutic in patients with metastatic melanoma; a completed preclinical program,
Why Should Investors Buy VICL After the Recent Fall? Just Go Here and Find Out
CytRx Corporation (NASDAQ:CYTR) the stock decreased -4.55% and finished the session at $4.62. Traded with volume of 1.65 million shares in the prior session and the average volume of the stock remained 4.18 million shares. The beta of the stock remained 1.21. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS.
Will CYTR Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)